Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PLS

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7383   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: PLS. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2018-000298-65 Sponsor Protocol Number: BAY1021189/19334 Start Date*: 2018-06-11
    Sponsor Name:Bayer AG
    Full Title: A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activi...
    Medical condition: Heart failure and preserved ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) AT (Completed) ES (Completed) HU (Completed) BG (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005470-12 Sponsor Protocol Number: Calc01 Start Date*: 2009-05-11
    Sponsor Name:Medical University of Vienna
    Full Title: Calcitonin Prophylaxis in Phantom Limb Pain
    Medical condition: Almost 60% of patients suffer from phantom limb pain one year after surgery, whereas in the first month, 85% to 97% of patients experience phantom limb pain. IV. calcitonin in the early postoperati...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034804 Phantom limb pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024265-40 Sponsor Protocol Number: KETA-FAN Start Date*: 2011-10-27
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE
    Full Title: Perineural vs systemic N-methyl-D-aspartate (NMDA) receptors antagonism with ketamine as a reverser of peripheral and central sensitization in phantom limb pain
    Medical condition: Phantom limb pain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10034804 Phantom limb pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000619-27 Sponsor Protocol Number: 56481676 Start Date*: 2007-08-13
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: Prospective, double-blind, randomised trial to assess the efficacy of continuous sciatic/posterior tibial nerve blockade via a neural sheath catheter in lower limb amputees
    Medical condition: Stump and phantom limb pain after lower limb amputation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056238 Phantom pain LLT
    9.1 10054711 Postoperative pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001388-71 Sponsor Protocol Number: CV185-017 Start Date*: 2005-11-30
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic ...
    Medical condition: Acute Symptomatic Deep Vein Thrombosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003442-16 Sponsor Protocol Number: D169EC00002 Start Date*: 2019-04-17
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients wi...
    Medical condition: Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003441-42 Sponsor Protocol Number: D169EC00001 Start Date*: 2019-05-22
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients wi...
    Medical condition: Heart Failure Patients with Preserved Ejection Fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) SK (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005893-37 Sponsor Protocol Number: CZOL446M2307 Start Date*: 2007-02-28
    Sponsor Name:NOVARTIS FARMA
    Full Title: A one year multicenter, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of a single intravenous 5 mg dose zoledronic acid for the treatment ...
    Medical condition: osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022808-40 Sponsor Protocol Number: CANALS Start Date*: 2011-01-13
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: A fase II, randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients
    Medical condition: amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002347-41 Sponsor Protocol Number: CA209-744 Start Date*: Information not available in EudraCT
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin...
    Medical condition: Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Ongoing) IE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) Outside EU/EEA IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019856-30 Sponsor Protocol Number: CLDE225B2307 Start Date*: 2010-06-29
    Sponsor Name:NOVARTIS FARMA
    Full Title: A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid B...
    Medical condition: Basal Cell Carcinoma in adult patients with Nevoid Basal Cell Carcinoma Syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004146 Basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000862-21 Sponsor Protocol Number: CSPP100A2353 Start Date*: 2008-06-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12 week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren...
    Medical condition: hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002877-30 Sponsor Protocol Number: CSOM230B2212 Start Date*: 2006-12-22
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning ad...
    Medical condition: duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning adenoma, TSH-adenoma,Gonadotroph adenoma, and PRL-adenoma)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10035098 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002171-16 Sponsor Protocol Number: BAY 59-7939 / 11528 Start Date*: 2005-01-10
    Sponsor Name:Bayer HealthCare AG
    Full Title: Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study.
    Medical condition: Acute syntomatic deep vein thrombosis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10051055
    Population Age: Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005294-60 Sponsor Protocol Number: CRAD001C24114 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Multicenter, triple-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis...
    Medical condition: histological evidence of progressive or metastatic bone or soft tissue sarcomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002449-19 Sponsor Protocol Number: LBH589C2204 Start Date*: 2008-05-08
    Sponsor Name:NOVARTIS FARMA
    Full Title: A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with...
    Medical condition: metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001822-23 Sponsor Protocol Number: CEPO906A2229 Start Date*: 2006-07-29
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer
    Medical condition: Cancer of the prostate is the most commonly diagnosed neoplasm in men in the United States after skin cancer. In 2002, over 189,000 new cases were diagnosed in United States representing 30% of all...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008697-31 Sponsor Protocol Number: CRAD001W2301 Start Date*: 2009-11-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing loc...
    Medical condition: HER2-neu overexpressing metastatic breast cancer after previous trastuzumab use
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) GR (Completed) BE (Completed) IT (Completed) ES (Completed) FR (Completed) CZ (Completed) GB (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000426-29 Sponsor Protocol Number: I1Q-MC-JDDE Start Date*: 2011-09-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty (eTHA)
    Medical condition: Disuse atrophy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10013521 Disuse muscle atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) EE (Completed) ES (Completed) SE (Completed) AT (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004367-22 Sponsor Protocol Number: CACZ885D2306 Start Date*: 2008-05-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1β monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated periodi...
    Medical condition: The following cryopyrin-associated periodic syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064569 Muckle-Wells syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Prematurely Ended) BE (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Oct 01 20:53:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA